BACKGROUND:Venous thromboembolism (VTE) after intracerebral hemorrhage is well studied, but data on patients with spontaneous intraventricular hemorrhage (IVH) are limited. OBJECTIVE: To study the factors associated with VTE, association between VTE and clinical outcomes in IVH, and safety of VTE chemoprophylaxis in IVH treated with intraventricular catheters and thrombolysis. METHODS: Retrospective cohort study of patients enrolled in the CLEAR III trial, a multicenter, randomized trial comparing external ventricular drainage, with administration of intraventricular alteplase vs placebo, for obstructive IVH. Predictor variable was incident VTE in the first 30 d. Outcome measures were factors associated with VTE, and death/severe disability (modified Rankin Score 4-6) at 6 mo. RESULTS: Of the 500 patients with IVH, VTE occurred in 59 patients (11.8%) within the first 30 d. VTE chemoprophylaxis was initiated in 412 (82.4%) patients, but before VTE diagnosis in only 401 (80.2%) at median of 4 d (interquartile range, 1-8) from IVH onset, and was not associated with intracranial bleeding or catheter tract hemorrhage. In the multivariate logistic regression analysis, infection within 30 d (odds ratio, 1.80; confidence interval, 1.03-3.17) was significantly associated with higher odds of VTE occurrence. Starting VTE chemoprophylaxis after 72 h was additionally associated with VTE occurrence after the first week. CONCLUSION: Infection and delay in timely initiation of VTE chemoprophylaxis were associated with VTE occurrence. VTE chemoprophylaxis in IVH appears safe and should not be delayed beyond standard care policies for ICH including when intraventricular catheter placement and thrombolytic therapy are performed.
RCT Entities:
BACKGROUND:Venous thromboembolism (VTE) after intracerebral hemorrhage is well studied, but data on patients with spontaneous intraventricular hemorrhage (IVH) are limited. OBJECTIVE: To study the factors associated with VTE, association between VTE and clinical outcomes in IVH, and safety of VTE chemoprophylaxis in IVH treated with intraventricular catheters and thrombolysis. METHODS: Retrospective cohort study of patients enrolled in the CLEAR III trial, a multicenter, randomized trial comparing external ventricular drainage, with administration of intraventricular alteplase vs placebo, for obstructive IVH. Predictor variable was incident VTE in the first 30 d. Outcome measures were factors associated with VTE, and death/severe disability (modified Rankin Score 4-6) at 6 mo. RESULTS: Of the 500 patients with IVH, VTE occurred in 59 patients (11.8%) within the first 30 d. VTE chemoprophylaxis was initiated in 412 (82.4%) patients, but before VTE diagnosis in only 401 (80.2%) at median of 4 d (interquartile range, 1-8) from IVH onset, and was not associated with intracranial bleeding or catheter tract hemorrhage. In the multivariate logistic regression analysis, infection within 30 d (odds ratio, 1.80; confidence interval, 1.03-3.17) was significantly associated with higher odds of VTE occurrence. Starting VTE chemoprophylaxis after 72 h was additionally associated with VTE occurrence after the first week. CONCLUSION:Infection and delay in timely initiation of VTE chemoprophylaxis were associated with VTE occurrence. VTE chemoprophylaxis in IVH appears safe and should not be delayed beyond standard care policies for ICH including when intraventricular catheter placement and thrombolytic therapy are performed.
Authors: Daniel F Hanley; Karen Lane; Nichol McBee; Wendy Ziai; Stanley Tuhrim; Kennedy R Lees; Jesse Dawson; Dheeraj Gandhi; Natalie Ullman; W Andrew Mould; Steven W Mayo; A David Mendelow; Barbara Gregson; Kenneth Butcher; Paul Vespa; David W Wright; Carlos S Kase; J Ricardo Carhuapoma; Penelope M Keyl; Marie Diener-West; John Muschelli; Joshua F Betz; Carol B Thompson; Elizabeth A Sugar; Gayane Yenokyan; Scott Janis; Sayona John; Sagi Harnof; George A Lopez; E Francois Aldrich; Mark R Harrigan; Safdar Ansari; Jack Jallo; Jean-Louis Caron; David LeDoux; Opeolu Adeoye; Mario Zuccarello; Harold P Adams; Michael Rosenblum; Richard E Thompson; Issam A Awad Journal: Lancet Date: 2017-01-10 Impact factor: 79.321
Authors: Elias Skaf; Paul D Stein; Afzal Beemath; Julia Sanchez; Mark A Bustamante; Ronald E Olson Journal: Am J Cardiol Date: 2005-11-02 Impact factor: 2.778
Authors: Daniel B Herrick; Wendy C Ziai; Carol B Thompson; Karen Lane; Nichol A McBee; Daniel F Hanley Journal: Stroke Date: 2011-09-22 Impact factor: 7.914
Authors: Neal Naff; Michael A Williams; Penelope M Keyl; Stanley Tuhrim; M Ross Bullock; Stephan A Mayer; William Coplin; Raj Narayan; Stephen Haines; Salvador Cruz-Flores; Mario Zuccarello; David Brock; Issam Awad; Wendy C Ziai; Anthony Marmarou; Denise Rhoney; Nichol McBee; Karen Lane; Daniel F Hanley Journal: Stroke Date: 2011-08-25 Impact factor: 7.914
Authors: Fadar Oliver Otite; Priyank Khandelwal; Amer M Malik; Seemant Chaturvedi; Ralph L Sacco; Jose G Romano Journal: Stroke Date: 2017-02-22 Impact factor: 7.914
Authors: Michael N Diringer; Brett E Skolnick; Stephan A Mayer; Thorsten Steiner; Stephen M Davis; Nikolai C Brun; Joseph P Broderick Journal: Stroke Date: 2009-12-03 Impact factor: 7.914
Authors: Wendy C Ziai; Stanley Tuhrim; Karen Lane; Nichol McBee; Kennedy Lees; Jesse Dawson; Kenneth Butcher; Paul Vespa; David W Wright; Penelope M Keyl; A David Mendelow; Carlos Kase; Christine Wijman; Marc Lapointe; Sayona John; Richard Thompson; Carol Thompson; Steven Mayo; Pat Reilly; Scott Janis; Issam Awad; Daniel F Hanley Journal: Int J Stroke Date: 2013-08-28 Impact factor: 5.266
Authors: Kara R Melmed; Amelia Boehme; Natasha Ironside; Santosh Murthy; Soojin Park; Sachin Agarwal; E Sander Connolly; Jan Claassen; Mitchell S V Elkind; David Roh Journal: Neurocrit Care Date: 2021-02 Impact factor: 3.210